ストックスクリーナーアプリを入手
1.65
4.43%
0.07
アフターアワーズ：
1.56
-0.09
-5.45%
前日終値:
$1.58
開ける：
$1.64
24時間の取引高:
80,800
Relative Volume:
0.32
時価総額：
$86.59M
収益：
-
当期純損益:
$-4.61M
株価収益率:
-13.16
EPS:
-0.1254
ネットキャッシュフロー:
$-3.10M
1週間 パフォーマンス:
+3.77%
1か月 パフォーマンス:
-0.60%
6か月 パフォーマンス:
-20.29%
1年 パフォーマンス:
+47.32%
1日の値動き範囲:
$1.5704
$1.71
1週間の範囲:
$1.47
$1.71
52週間の値動き範囲:
$1.1002
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.65 | 82.92M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Piper Sandler | Overweight |
| 2025-12-08 | 開始されました | B. Riley Securities | Buy |
Okyo Pharma Limited (OKYO) 最新ニュース
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March - MarketBeat
Aug Action: How does OKYO Pharma Limited compare to its peers - baoquankhu1.vn
Aug Sentiment: Is OKYO Pharma Limited a turnaround storyMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Gap Down: Can OKYO Pharma Limited beat the S P 5002026 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting - Sahm
Small cap wrap: Replenish Nutrients, OKYO Pharma, Bit Digital, Record Resources… - Proactive financial news
OKYO Pharma to hold advisory board meeting at ASCRS conference By Investing.com - Investing.com South Africa
OKYO Pharma to hold advisory board meeting at ASCRS annual event - Investing.com India
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 - Yahoo Finance
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting - TipRanks
OKYO Pharma to hold advisory board meeting at ASCRS annual event By Investing.com - Investing.com South Africa
OKYO Pharma to hold advisory board meeting at ASCRS conference - Investing.com
OKYO Pharma (OKYO) showcases urcosimod Phase 2 data and plans 150-patient trial - Stock Titan
OKYO Pharma Announces Scientific Advisory Board Meeting and - GlobeNewswire
Income Plays: Is OKYO Pharma Limited stock trending bullishPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
OKYO SEC FilingsOKYO PHARMA LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-03-31 02:21:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - The Globe and Mail
OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK
OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma Announces Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - in.investing.com
OKYO Pharma announces director stock purchase - proactiveinvestors.com
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) CDO buys 30,980 shares at $1.59 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive Investors
Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial - Investing.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times
OKYO Pharma LTD - Via Ritzau
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat
Okyo Pharma Limited (OKYO) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):